Relapsed/Refractory Archives

September 13, 2022

ASH 2021: Safety and Efficacy of Third Generation CD20 Targeted CAR-T (MB-106) for Treatment of Relapsed/Refractory B-NHL and CLL

Dr. Mazyar Shadman and colleagues presented this research at the American Society for Hematology annual meeting, which was held in December 2021 (ASH 2021).

August 26, 2022

ASH 2021: Phase 1/2 Trial of IL7/IL15-Expanded Bispecific LV20.19 CAR T-Cells for Relapsed, Refractory B-Cell Non-Hodgkin Lymphoma

These results are encouraging and show that patients with relapsed/refractory B-cell NHL treated with bispecific LV20.19 CAR T-cells have a high overall response rate and low rates of grade ≥3 CRS or ICANS.

August 25, 2022

EHA 2022: Outcomes Following Treatment With a Covalent BTK and BCL2 Inhibitor Among Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): A Real-World Study of a Large U.S. Database

Some see CLL/SLL as a solved problem. But unfortunately, we know better. This abstract from the European Hematology Association (EHA) Annual Congress in 2022 reinforced one of our greatest unsolved problems: what happens following treatment with a covalent BTK and BCL2 inhibitor.

August 25, 2022

ASCO 2022: Acalabrutinib Versus Rituximab Plus Idelalisib or Bendamustine in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL): ASCEND Results at 4 Years of Follow-Up

At the American Society of Clinical Oncology (ASCO) Annual Meeting in 2022, we received the four-year follow-up data update on the ASCEND trial. This trial compared acalabrutinib (acala) to the treating doctor’s choice of rituximab plus idelalisib (IdR) or bendamustine (BR) in relapsed/refractory (R/R) chronic lymphocytic leukemia.

August 17, 2022

Noncovalent BTK Inhibitors Could Address One of the Biggest Unmet Needs in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

nubrutinib) and the only approved BCL2 blocker (venetoclax) are referred to as being double refractory. Double refractory disease is one of the greatest unmet needs in CLL/SLL.

July 27, 2022

ASH 2021: Dr. Megan Thompson on Outcomes of Subsequent Therapies after Exposure to Bruton’s Tyrosine Kinase Inhibitors and Venetoclax

We discuss results from two new studies, which looked at real-world outcomes of subsequent therapies in patients whose disease progressed after either 1) double-exposure to a covalent BTK inhibitor and venetoclax or 2) exposure to a non-covalent BTK inhibitor.

July 27, 2022

ASH 2021: Dr. Jeff Sharman on Zanubrutinib for BTK Inhibitor-Intolerant Patients with Chronic Lymphocytic Leukemia (CLL)

At the American Society of Hematology (ASH) 2021, our own Dr. Brian Koffman interviewed Dr. Jeff Sharman, a hematologist/oncologist at Willamette Valley Cancer Institute in Eugene, OR. They discussed zanubrutinib and its use in patients who could not tolerate previous BTK inhibitors.

July 13, 2022

ASH 2021 – Outcomes of Patients with Chronic Lymphocytic Leukemia (CLL) Treated with the Combination of Ibrutinib (I) and Venetoclax (V; I+V) After Progression on I Alone (V-naïve) or After Progression on Sequential I and V (Double Refractory)

Outcomes of Patients with Chronic Lymphocytic Leukemia (CLL) Treated with the Combination of Ibrutinib (I) and Venetoclax (V; I+V) After Progression on I Alone (V-naïve) or after Progression on Sequential I and V (Double Refractory)

July 13, 2022

ASH 2021: Dr. John Seymour on Acquired Mutations in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) After Fixed-Duration Venetoclax-Rituximab Treatment

We discussed an analysis of acquired mutations in patients from the MURANO trial whose disease had progressed.

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Relapsed/Refractory

ASH 2021: Safety and Efficacy of Third Generation CD20 Targeted CAR-T (MB-106) for Treatment of Relapsed/Refractory B-NHL and CLL

ASH 2021: Phase 1/2 Trial of IL7/IL15-Expanded Bispecific LV20.19 CAR T-Cells for Relapsed, Refractory B-Cell Non-Hodgkin Lymphoma

EHA 2022: Outcomes Following Treatment With a Covalent BTK and BCL2 Inhibitor Among Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): A Real-World Study of a Large U.S. Database

ASCO 2022: Acalabrutinib Versus Rituximab Plus Idelalisib or Bendamustine in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL): ASCEND Results at 4 Years of Follow-Up

Noncovalent BTK Inhibitors Could Address One of the Biggest Unmet Needs in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

ASH 2021: Dr. Megan Thompson on Outcomes of Subsequent Therapies after Exposure to Bruton’s Tyrosine Kinase Inhibitors and Venetoclax

ASH 2021: Dr. Jeff Sharman on Zanubrutinib for BTK Inhibitor-Intolerant Patients with Chronic Lymphocytic Leukemia (CLL)

ASH 2021 – Outcomes of Patients with Chronic Lymphocytic Leukemia (CLL) Treated with the Combination of Ibrutinib (I) and Venetoclax (V; I+V) After Progression on I Alone (V-naïve) or After Progression on Sequential I and V (Double Refractory)

ASH 2021: Dr. John Seymour on Acquired Mutations in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) After Fixed-Duration Venetoclax-Rituximab Treatment

CLL SOCIETY FAST FIND

QUICK LINKS

ABOUT US

CONTACT